This website is intended for healthcare professionals only.
Pr. BRIDGEWATER on several research and funding committees including the clinical trials advisory and awards committee, asco, inserm, inca, mrc, kwf and national institute for health and care excellence committees
Fabio KATER, MD, oncologist at the beneficencia portuguesa and the author of numerous publications concerning prostaste cancer
This webinar tells the journey of a real-life patient with intrahepatic cholangiocarcinoma (iCCA) who was treated with second-line ivosidenib and became a long-term responder. The speakers discuss the importance of molecular testing, different biopsy methods and give recommendations from the latest guidelines. They also review the efficacy and safety profile of ivosidenib based on data from the ClarIDHy trial, and post hoc data long-term response data
Key points covered
This webinar looks at the patient journey of an ivosidenib long-term responder patient with iCCA
Patients with iCCA face poor outcomes due to the common late stage at diagnosis and aggressive nature of the disease
Molecular testing for actionable mutations, such as IDH1, and targeted therapies are recommended by guidelines to help determine 2L treatment choice
The effiacy and safety profile of ivosidenib in iCCA is established. Post hoc data showed long-term disease stability and tumor shrinkage in patients who received ivosidenib for ≥1 year
Webinar highlights
Full webinar replay
Featured Speakers
PROFESSOR BRIDGEWATER ON SEVERAL RESEARCH AND FUNDING COMMITTEES INCLUDING THE CLINICAL TRIALS ADVISORY AND AWARDS COMMITTEE, ASCO, INSERM, INCA, MRC, KWF AND NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE COMMITTEES
After qualifying in medicine and surgery in 1986 from Oxford and UCL, Professor Bridgewater specialised in medical oncology at the Middlesex, Mount Vernon and Royal Marsden Hospitals. He undertook a PhD in gene therapy at the Institute of Cancer Research, and subsequently accepted a senior lecturer position in medical oncology at UCL in 1999 in parallel with a consultant position at University College London Hospitals.
Professor Bridgewater has led the National Cancer Research Institute (NCRI) Study Group in upper gastrointestinal malignancy and has directed several landmark studies in gastrointestinal (GI) malignancy. He leads the Genomics England UGI theme, incorporating genomics into standard of care and research agendas. He specialises in the personalised oncology of gastrointestinal malignancies.
FABIO KATER, MD, ONCOLOGIST AT THE BENEFICENCIA PORTUGUESA AND THE AUTHOR OF NUMEROUS PUBLICATIONS CONCERNING PROSTASTE CANCER
Fabio Kater, MD, is an oncologist at the Beneficencia Portuguesa and the author of numerous publications concerning prostate cancer. He is also a renowned contributor for Oncologia Brasil and is a speaker at the ASCO24. He is one of the investigators in a controlled trial investigating consolidation chemotherapy in distal rectal cancer.
